Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma

Modern Pathology

Volumn 26, Issue 8, 2013, Pages 1132-1143

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Claudin 4; Immunohistochemistry; Mesothelioma; Napsin A; PAX2; PAX8; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; CLAUDIN 4; NAPSIN A; PROTEIN; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ANTIGEN RETRIEVAL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; PH; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANTIGENS, NEOPLASM; ASPARTIC ACID ENDOPEPTIDASES; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CLAUDIN-4; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; HUMANS; KIDNEY NEOPLASMS; MESOTHELIOMA; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84881314816     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.34     Document Type: Article

References (118)

1. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13: 276-291.
2. Wick MR, Loy T, Mills SE, et al. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: A histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-766.
3. Brown RW, Clark GM, Tandon AK, et al. Multiplemarker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24: 347-354.
4. Oates J, C Edwards. HBME-1, MOC-31, WT1 and calretinin: As assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
5. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: A study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
6. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: A useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529-536.
7. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
8. Attanoos RL, Goddard H, Thomas ND, et al. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: The diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Histopathology 1995;27:361-366.
9. Osborn M, Pelling N, Walker MM, et al. The value of 'mesothelium- associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Histopathology 2002;41:301-307.
10. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: A comparative study. Hum Pathol 2004;35:697-710.
11. Cavazza A, Pasquinelli G, Agostini L, et al. Foamy cell mesothelioma. Histopathology 2002;41:369-371.
12. Ordóñez NG. Mesothelioma with clear cell features: An ultrastructural and immunohistochemical study of 20 cases. Hum Pathol 2005;36:465-473.
13. Latour A, Shulman HS. Thoracic manifestations of renal cell carcinoma. Radiology 1976;121:43-48.
14. Taylor DR, Page W, Hughes D, et al. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Thorax 1987;42:901-902.
15. Azuma T, Nishimatsu H, Nakagawa T, et al. Metastatic renal cell carcinoma mimicking pleural mesothelioma. Scand J Urol Nephrol 1999;33:140-141.
16. Attanoos RL, Gibbs AR. 'Pseudomesotheliomatous' carcinomas of the pleura: A 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology 2003;43:444-452.
17. Ohnishi H, Abe M, Hamada H, et al. Metastatic renal cell carcinoma presenting as multiple pleural tumours. Respirology 2005;10:128-131.
18. Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995;61:601-605.
19. Sali D, Boffetta P. Kidney cancer and occupational exposure to asbestos: A meta-analysis of occupational cohort studies. Cancer Causes Control 2000;11:37-47.
20. Roberts GH. Distant visceral metastases in pleural mesothelioma. Br J Dis Chest 1976;70:246-250.
21. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 2011;135:92-109.
22. Stoykova A, Gruss P. Roles of Pax-genes in developing and adult brain as suggested by expression patterns. J Neurosci 1994;14:1395-1412.
23. Mittag J, Winterhager E, Bauer K, et al. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007;148:719-725.
24. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: An immunohistochemical study. Mod Pathol 2009;22:1218-1227.
25. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: A comprehensive immunohistochemical study. Mod Pathol 2011;24: 751-764.
26. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011;19:293-299.
27. Fujiwara M, Taube J, Sharma M, et al. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. J Cutan Pathol 2010;37:938-943.
28. Carney EM, Banerjee P, Ellis CL, et al. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol 2011;35:262-267.
29. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: A study of 248 cases. Am J Surg Pathol 2011;35:678-686.
30. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010;34:627-635.
31. Ordóñez NG. Value of PAX 8 immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol 2012;19:140-151.
32. Torres M, Gómez-Pardo E, Dressler GR, et al. Pax-2 controls multiple steps of urogenital development. Development 1995;121:4057-4065.
33. Dressler GR, Woolf AS. Pax2 in development and renal disease. Int J Dev Biol 1999;43:463-468.
34. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol 2001;32:282-287.
35. Gupta R, Balzer B, Picken M, et al. Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol 2009;33:241-247.
36. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2010;18:323-332.
37. Mazal PR, Stichenwirth M, Koller A, et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: A tissue microarray study. Mod Pathol 2005;18:535-540.
38. Memeo L, Jhang J, Assaad AM, et al. Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: Value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol 2007;127:225-229.
39. Wasco MJ, Pu RT. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration. Diagn Cytopathol 2008;36:568-573.
40. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis of primary renal tumors: Immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol 2009;131:393-404.
41. Carvalho JC, Wasco MJ, Kunju LP, et al. Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C-kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. Histopathology 2011;58:169-179.
42. Sharma SG, Gokden M, McKenney JK, et al. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol 2010;18:494-498.
43. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: An immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008;32:1462-1467.
44. Rivera AL, Takei H, Zhai J, et al. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology 2010;30:580-585.
45. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: Immunohistochemical evidence of fallopian tube or secondary Mü llerian system origiñMod Pathol 2007;20:856-863.
46. Ordóñez NG. Value of PAX2 Immunostaining in tumor diagnosis: A review and update. Adv Anat Pathol 2012;19:401-409.
47. Ordóñez NG. Napsin A expression in lung and kidney neoplasia: A review and update. Adv Anat Pathol 2012;19:66-73.
48. Mori K, Shimizu H, Konno A, et al. Immunohistochemical localization of napsin and its potential role in protein catabolism in renal proximal tubules. Arch Histol Cytol 2002;65:359-368.
49. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): Extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 2010;34:1295-1303.
50. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41: 20-25.
51. Stoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010;118:441-449.
52. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol 2011;19:313-317.
53. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003;41:155-162.
54. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007;35:493-497.
55. Amatya VJ, Takeshima Y, Kohno H, et al. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology 2009;55:10-19.
56. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401.
57. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2-7.
58. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160-6165.
59. Liao SY, Aurelio ON, Jan K, et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997;57:2827-2831.
60. Tostain J, Li G, Gentil-Perret A, et al. Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer 2010;46:3141-3148.
61. Leppert JT, Lam JS, Pantuck AJ, et al. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 2005;96:281-285.
62. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007;25:4757-4764.
63. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: An immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008;32:377-382.
64. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: Correlation with tumor type and grade. Am J Clin Pathol 2010;134:873-879.
65. McKenney JK, Fujiwara M, Higgins JP, et al. Comparison of putative renal cell carcinoma (RCC) immunohistochemical (IHC) markers in primary adrenal cortical lesions (ACL) and metastatic RCC: A tissue microarray study of 246 cases. Mod Pathol 2009;22(Suppl 1):182A.
66. Osunkoya AO, Yin-Goen Q, Phan JH, et al. Diagnostic biomarkers for renal cell carcinoma: Selection using novel bioinformatics systems for microarray data analysis. Hum Pathol 2009;40:1671-1678.
67. Lapinski JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: Utility of immunohistochemical markers. Appl Immunohistochem Mol Morphol 2010;18:414-421.
68. Prayson RA, Chamberlain WA, Angelov L. Clear cell meningioma: A clinicopathologic study of 18 tumors and examination of the use of CD10, CA9, and RCC antibodies to distinguish between clear cell meningioma and metastatic clear cell renal cell carcinoma. Appl Immunohistochem Mol Morphol 2010;18: 422-428.
69. Ramsey ML, Yuh BJ, Johnson MT, et al. Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung. Virchows Arch 2012;460:89-93.
70. Ivanov S, Liao SY, Ivanova A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905-919.
71. Yoshida SO, Imam A. Monoclonal antibody to a proximal nephrogenic renal antigen: Immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Res 1989;49:1802-1809.
72. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000;24:203-210.
73. Pan CC, Chen PC, Ho DM. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: An immunohistochemical analysis of 328 cases. Histopathology 2004;45:452-459.
74. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: The use of the monoclonal antibody 'renal cell carcinoma marker'. Am J Surg Pathol 2001;25:1485-1492.
75. Butnor KJ, Nicholson AG, Allred DC, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006;130:823-827.
76. Bakshi N, Kunju LP, Giordano T, et al. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: Diagnostic implications. Appl Immunohistochem Mol Morphol 2007;15:310-315.
77. Allory Y, Bazille C, Vieillefond A, et al. Profiling and classification tree applied to renal epithelial tumours. Histopathology 2008;52:158-166.
78. Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: A systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 2005;13:347-352.
79. Ingold B, Wild PJ, Nocito A, et al. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology 2008;52:674-681.
80. Yan M, Ghorab Z, Nadji M. Renal cell carcinoma antigen is expressed by yolk sac tumors and yolk sac elements of embryonal carcinomas. Appl Immunohistochem Mol Morphol 2003;11:113-115.
81. Ritz J, Pesando JM, Notis-McConarty J, et al. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature 1980;283:583-585.
82. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001;39:273-278.
83. Xiao SY, Wang HL, Hart J, et al. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma. Am J Pathol 2001;159:1415-1421.
84. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002;10: 332-338.
85. Langner C, Ratschek M, Rehak P, et al. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 2004;45:460-467.
86. Martignoni G, Pea M, Brunelli M, et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 2004;17:1455-1463.
87. Paner GP, Srigley JR, Radhakrishnan A, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: Significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol 2006;30:13-19.
88. Liu L, Qian J, Singh H, et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: An optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 2007;131:1290-1297.
89. Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451:669-680.
90. Soini Y, Kinnula V, Kahlos K, et al. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 2006;59:250-254.
91. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: A review and update. Hum Pathol 2012;44:1-19.
92. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005;46: 551-560.
93. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
94. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
95. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: Analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol 2001;25:610-617.
96. Martignoni G, Pea M, Chilosi M, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol 2001;14:760-767.
97. Lugli A, Forster Y, Haas P, et al. Calretinin expression in human normal and neoplastic tissues: A tissue microarray analysis on 5233 tissue samples. Hum Pathol 2003;34:994-1000.
98. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18: 105-110.
99. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
100. Nolan LP, Heatley MK. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary. Int J Gynecol Pathol 2001;20:155-159.
101. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: Potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005;29:747-754.
102. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
103. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 2008;36:20-25.
104. Muir TE, Cheville JC, Lager DJ. Metanephric adenoma, nephrogenic rests, andWilms' tumor: A histologic and immunophenotypic comparison. Am J Surg Pathol 2001;25:1290-1296.
105. Chute DJ, Kong CS, Stelow EB. Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology. Diagn Cytopathol 2011;39:118-123.
106. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-158.
107. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
108. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-197.
109. Galloway ML, Murray D, Moffat DF. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. Histopathology 2006;48:767-769.
110. Frierson HF Jr, Moskaluk CA, Powell SM, et al. Largescale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-609.
111. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-833.
112. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: A comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21: 1399-1408.
113. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21: 1409-1419.
114. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-862.
115. Husain AN, Colby T, Ordóñez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2012 (e-pub ahead of print).
116. Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol 2005;36:1163-1167.
117. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol 2006;19: 417-428.
118. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 2012 (e-pub ahead of print).